Clinical trial
A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia
NCT07936201 is registered in ClinicalTrials.gov with Case Comprehensive Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multi-Institutional Study of Combination of Luspatercept With Pacritinib (LusPACercept) in Patients With Myelofibrosis Associated Anemia and Thrombocytopenia
- Lead sponsor
- Case Comprehensive Cancer Center
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- January 1, 2029
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
myelofibrosis
Arms
As registered; 1 arm.
-
LusPACercept combination
Luspatercept will be given through subcutaneous injection on Day 1of each cycle at a starting dose of 1.33 milligrams/kilogram and can go up to a maximum dose of 1.75 milligrams/kilogram. Pacritinib will be given twice daily orally at a dose of 200 milligrams. Each cycle lasts 21 days.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Rate of major response for anemia
The rate of major response for anemia is defined as per 2024 IWG-ELN response criteria for transfusion dependent and non-transfusion dependent partipants with myelofibrosis.
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Luspatercept
- US 8058229; expires November 8, 2033; assignee Acceleron Pharma (United States)
-
Pacritinib
- US 8980873; expires March 25, 2030; assignee CTI BioPharma (United States)
- US 8153632; expires January 17, 2029; assignee S*BIO Pte Ltd
- US 9573964; expires May 5, 2028; assignee CTI BioPharma (United States)
Lead sponsor's other trials
Case Comprehensive Cancer Center, most recent start first.
+489 more trials See the organization page
Similar trials
Same condition (Primary Myelofibrosis) and phase, most recent start first.
+203 more trials See the condition page